阅读说明：本技术 拉莫三嗪悬浮剂剂型 (Lamotrigine suspension formulations ) 是由 K.S.梅塔 D.库玛尔 S.斯里瓦斯塔瓦 A.贾 R.K.辛格 于 2018-02-02 设计创作，主要内容包括：本发明涉及用于拉莫三嗪及其药学上可接受的盐的口服悬浮剂剂型的稳定的即用型粉末,和制备这种组合物的方法。用于拉莫三嗪的口服悬浮剂剂型的液体和粉末以前仅作为临时制剂已知。本发明涉及用于拉莫三嗪的口服悬浮剂剂型的液体和粉末的制备,其具有改进的物理化学性质,从而满足所期望的技术属性。所制备的剂型可用于在吞咽片剂方面有困难的患者,并为医生提供更多的对剂量进行调整的选择性。(The present invention relates to stable ready-to-use powders for oral suspension dosage forms of lamotrigine and pharmaceutically acceptable salts thereof, and to a process for preparing such compositions. Liquids and powders for oral suspension dosage forms of lamotrigine have previously been known only as extemporaneous formulations. The present invention relates to the preparation of liquids and powders for oral suspension dosage forms of lamotrigine having improved physicochemical properties, thereby satisfying the desired technical attributes. The dosage forms prepared are useful for patients who have difficulty swallowing tablets and provide the physician with more options for adjusting the dosage.)